Alexander C J van Akkooi
Overview
Explore the profile of Alexander C J van Akkooi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
4497
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mo J, Zaremba A, Inderjeeth A, El Zeinaty P, Li A, Wicky A, et al.
Eur J Cancer
. 2025 Jan;
217:115254.
PMID: 39874912
Aim: Merkel Cell Carcinoma (MCC) is a rare skin cancer with a rising incidence worldwide. Anti-programmed death-1/ligand-1 (anti-PD-(L)1) therapies are effective for the treatment of advanced MCC. This study examines...
2.
Wu Z, Nickel B, Boroumand F, Elder D, Ferguson P, Scolyer R, et al.
BMJ Open
. 2025 Jan;
14(12):e089558.
PMID: 39806624
Introduction: A diagnosis of melanoma in situ presents negligible risk to a person's lifespan or physical well-being, but existing terminology makes it difficult for patients to distinguish these from higher...
3.
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.
Eur J Cancer
. 2024 Dec;
215:115153.
PMID: 39709737
A unique collaboration of multi-disciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), and the European Organization of Research and Treatment of Cancer (EORTC) was...
4.
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al.
Eur J Cancer
. 2024 Dec;
215:115152.
PMID: 39700658
This guideline was developed in close collaboration with multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF) and the European Organization for Research and Treatment...
5.
Novis E, Sulaiman A, Stretch J, Chung D, London K, Wong T, et al.
Eur J Surg Oncol
. 2024 Dec;
51(2):109538.
PMID: 39662108
Background: Although most melanomas drain to the more common major lymph node basins (axilla, groin, neck), rarely they drain to deep SLN locations such as intra-abdominal and intra-thoracic (including intercostal...
6.
Reijers I, Menzies A, Lopez-Yurda M, Versluis J, Rozeman E, Saw R, et al.
Eur J Cancer
. 2024 Nov;
214():115141.
PMID: 39602990
Background: Pathologic response following neoadjuvant immune checkpoint blockade (ICB) in stage III melanoma serves as a surrogate marker for long-term outcomes. This may support more personalized, response-directed treatment strategies. Methods:...
7.
Weber J, Haque W, Markovic S, Salama A, Mehmi I, Sullivan R, et al.
Oncologist
. 2024 Nov;
PMID: 39560953
Background: In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF/MEK inhibitors...
8.
DePalo D, Dugan M, Naqvi S, Ollila D, Hieken T, Block M, et al.
Cancer
. 2024 Nov;
131(1):e35636.
PMID: 39522025
Background: Isolated limb infusion and perfusion (ILI/ILP) has been a mainstay treatment for unresectable melanoma in-transit metastases (ITM), but increased use of immune checkpoint inhibitors (ICI) and intralesional therapy (talimogene...
9.
Eggermont A, Kicinski M, Blank C, Mandala M, Long G, Atkinson V, et al.
Eur J Cancer
. 2024 Sep;
211:114327.
PMID: 39288737
Methods: We randomized 1019 patients to receive pembrolizumab 200 mg or placebo, intravenously every 3 weeks for a total of 18 doses. RFS in the overall population and in the...
10.
Holmberg C, Zijlker L, Katsarelias D, Huibers A, Wouters M, Schrage Y, et al.
Eur J Surg Oncol
. 2024 Sep;
50(12):108653.
PMID: 39266404
No abstract available.